RTTNews | Sep 20, 2021 08:24AM EDT

08:24 Monday, September 20, 2021 (RTTNews.com) - Bristol Myers Squibb (BMY) said FDA has accepted for priority review the Biologics License Application for relatlimab and nivolumab fixed-dose combination in the treatment of adult and pediatric patients with unresectable or metastatic melanoma. The BLA submission was based on the efficacy and safety results of the phase 2/3 RELATIVITY-047 trial. The FDA assigned a PDUFA goal date of March 19, 2022.

Bristol Myers Squibb is currently evaluating relatlimab, LAG-3-blocking antibody, in clinical trials in combination with other agents in a variety of tumor types.

Read the original article on RTTNews ( https://www.rttnews.com/3226840/bristol-myers-reports-fda-priority-review-for-relatlimab-and-nivolumab-combination.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved